Clinical trial
Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
NCT00290745 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00290745 |
|---|---|
| Title | Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ |
| Official title | Primary Hormonal Therapy for Ductal Carcinoma in Situ: Exploration of a Novel Approach to the Clinical Management of Noninvasive Breast Cancer |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Procedure |
| Interventions | letrozole, tamoxifen citrate, conventional surgery, neoadjuvant therapy |
| Enrollment | 79 |
| Start date | Feb 19, 2002 |
| Primary completion | Jul 31, 2009 |
| Completion | Jun 30, 2011 |
| First posted | Feb 13, 2006 |
| Last update posted | Dec 4, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: